论文部分内容阅读
目的:分析探讨培美曲塞联合奈达铂治疗非小细胞肺癌的临床疗效。方法:选取我院收治的48例行培美曲塞联合奈达铂治疗的非小细胞肺癌患者作为本次的研究对象,并对其临床资料进行回顾性分析。结果:本组48例患者均完成2个周期以上的化疗,其中完全缓解4例,部分缓解19例,稳定17例,进展8例,其总有效率为54.2%。患者主要不良反应为骨髓抑制、胃肠道反应、发热、皮疹、脱发等。结论:给予非小细胞肺癌患者培美曲塞联合奈达铂治疗可取得良好的效果,且毒性反应少,安全性高,有较高的应用价值,可推广应用。
Objective: To investigate the clinical efficacy of pemetrexed combined with nedaplatin in the treatment of non-small cell lung cancer. Methods: Forty-eight patients with non-small cell lung cancer treated with pemetrexed combined with nedaplatin in our hospital were selected as the study subjects and their clinical data were retrospectively analyzed. Results: All the 48 patients completed 2 cycles of chemotherapy. Among them, 4 were completely relieved, 19 were partially relieved, 17 were stable, and 8 were progress. The total effective rate was 54.2%. The main adverse reactions in patients with bone marrow suppression, gastrointestinal reactions, fever, rash, hair loss and so on. Conclusion: Pemetrexed combined with nedaplatin given in patients with non-small cell lung cancer can achieve good results with less toxic reaction, high safety and high application value.